530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population

530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Open forum infectious diseases 2021-12, Vol.8 (Supplement_1), p.S365-S366
Hauptverfasser: Curtin, John M, Costello, Varea H, Custer, Benjamin L, Blaylock, Jason M, Decker, Catherine F, Ressner, Roseanne, Robinson, Sara, Campbell, Wesley R, Blyth, Dana M, Ganesan, Anuradha
Format: Artikel
Sprache:eng
Schlagworte:
Poster Abstracts
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page S366
container_issue Supplement_1
container_start_page S365
container_title Open forum infectious diseases
container_volume 8
creator Curtin, John M
Costello, Varea H
Custer, Benjamin L
Blaylock, Jason M
Decker, Catherine F
Ressner, Roseanne
Robinson, Sara
Campbell, Wesley R
Blyth, Dana M
Ganesan, Anuradha
description
doi_str_mv 10.1093/ofid/ofab466.729
format Article
fullrecord <record><control><sourceid>pubmedcentral_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8643844</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>pubmedcentral_primary_oai_pubmedcentral_nih_gov_8643844</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1389-68769ae8a10deb16f094a5751dcf66ff27f8070d04f20d2f7d39e6187be75a463</originalsourceid><addsrcrecordid>eNpVkU1LAzEQhhdRsNTePeaoh63JfiRZD8K2WCtYlPpxDbObpI3uJmWzLdQ_419124roZWbgfedlmCcIzgkeEpzFV04b2RUoEkqHLMqOgl4URzzkWcqO_8ynwcD7d4wxITjFLOsFX2mMh2gEdQXWbEwNBboY5bNLpF2DnvP5czh2b2GE7q1WZWucvUZzaJVHYCWaG_-BJlC2rvH7hanzK9NCZT5h50WgW9WgmbOurJyFCuW2NYWTW5TL2ljj2-ZgNJ0XTc1iGe4zn9xqXe2Vs-BEQ-XV4Kf3g9fJ7ct4Gj483t2P84ewJDHPQsoZzUBxIFiqglCNswRSlhJZakq1jpjmmGGJEx1hGWkm40xRwlmhWAoJjfvBzSF3tS5qJUtlu9MqsWq6lzRb4cCI_4o1S7FwG8FpEvMk6QLwIaBsnPeN0r-7BIsdJLGDJH4giQ5S_A0jLYk6</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population</title><source>DOAJ Directory of Open Access Journals</source><source>Oxford Journals Open Access Collection</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><creator>Curtin, John M ; Costello, Varea H ; Custer, Benjamin L ; Blaylock, Jason M ; Decker, Catherine F ; Ressner, Roseanne ; Robinson, Sara ; Campbell, Wesley R ; Blyth, Dana M ; Ganesan, Anuradha</creator><creatorcontrib>Curtin, John M ; Costello, Varea H ; Custer, Benjamin L ; Blaylock, Jason M ; Decker, Catherine F ; Ressner, Roseanne ; Robinson, Sara ; Campbell, Wesley R ; Blyth, Dana M ; Ganesan, Anuradha</creatorcontrib><identifier>ISSN: 2328-8957</identifier><identifier>EISSN: 2328-8957</identifier><identifier>DOI: 10.1093/ofid/ofab466.729</identifier><language>eng</language><publisher>US: Oxford University Press</publisher><subject>Poster Abstracts</subject><ispartof>Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S365-S366</ispartof><rights>The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643844/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8643844/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,864,885,27923,27924,53790,53792</link.rule.ids></links><search><creatorcontrib>Curtin, John M</creatorcontrib><creatorcontrib>Costello, Varea H</creatorcontrib><creatorcontrib>Custer, Benjamin L</creatorcontrib><creatorcontrib>Blaylock, Jason M</creatorcontrib><creatorcontrib>Decker, Catherine F</creatorcontrib><creatorcontrib>Ressner, Roseanne</creatorcontrib><creatorcontrib>Robinson, Sara</creatorcontrib><creatorcontrib>Campbell, Wesley R</creatorcontrib><creatorcontrib>Blyth, Dana M</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><title>530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population</title><title>Open forum infectious diseases</title><subject>Poster Abstracts</subject><issn>2328-8957</issn><issn>2328-8957</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkU1LAzEQhhdRsNTePeaoh63JfiRZD8K2WCtYlPpxDbObpI3uJmWzLdQ_419124roZWbgfedlmCcIzgkeEpzFV04b2RUoEkqHLMqOgl4URzzkWcqO_8ynwcD7d4wxITjFLOsFX2mMh2gEdQXWbEwNBboY5bNLpF2DnvP5czh2b2GE7q1WZWucvUZzaJVHYCWaG_-BJlC2rvH7hanzK9NCZT5h50WgW9WgmbOurJyFCuW2NYWTW5TL2ljj2-ZgNJ0XTc1iGe4zn9xqXe2Vs-BEQ-XV4Kf3g9fJ7ct4Gj483t2P84ewJDHPQsoZzUBxIFiqglCNswRSlhJZakq1jpjmmGGJEx1hGWkm40xRwlmhWAoJjfvBzSF3tS5qJUtlu9MqsWq6lzRb4cCI_4o1S7FwG8FpEvMk6QLwIaBsnPeN0r-7BIsdJLGDJH4giQ5S_A0jLYk6</recordid><startdate>20211204</startdate><enddate>20211204</enddate><creator>Curtin, John M</creator><creator>Costello, Varea H</creator><creator>Custer, Benjamin L</creator><creator>Blaylock, Jason M</creator><creator>Decker, Catherine F</creator><creator>Ressner, Roseanne</creator><creator>Robinson, Sara</creator><creator>Campbell, Wesley R</creator><creator>Blyth, Dana M</creator><creator>Ganesan, Anuradha</creator><general>Oxford University Press</general><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>20211204</creationdate><title>530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population</title><author>Curtin, John M ; Costello, Varea H ; Custer, Benjamin L ; Blaylock, Jason M ; Decker, Catherine F ; Ressner, Roseanne ; Robinson, Sara ; Campbell, Wesley R ; Blyth, Dana M ; Ganesan, Anuradha</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1389-68769ae8a10deb16f094a5751dcf66ff27f8070d04f20d2f7d39e6187be75a463</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Poster Abstracts</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Curtin, John M</creatorcontrib><creatorcontrib>Costello, Varea H</creatorcontrib><creatorcontrib>Custer, Benjamin L</creatorcontrib><creatorcontrib>Blaylock, Jason M</creatorcontrib><creatorcontrib>Decker, Catherine F</creatorcontrib><creatorcontrib>Ressner, Roseanne</creatorcontrib><creatorcontrib>Robinson, Sara</creatorcontrib><creatorcontrib>Campbell, Wesley R</creatorcontrib><creatorcontrib>Blyth, Dana M</creatorcontrib><creatorcontrib>Ganesan, Anuradha</creatorcontrib><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Open forum infectious diseases</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Curtin, John M</au><au>Costello, Varea H</au><au>Custer, Benjamin L</au><au>Blaylock, Jason M</au><au>Decker, Catherine F</au><au>Ressner, Roseanne</au><au>Robinson, Sara</au><au>Campbell, Wesley R</au><au>Blyth, Dana M</au><au>Ganesan, Anuradha</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population</atitle><jtitle>Open forum infectious diseases</jtitle><date>2021-12-04</date><risdate>2021</risdate><volume>8</volume><issue>Supplement_1</issue><spage>S365</spage><epage>S366</epage><pages>S365-S366</pages><issn>2328-8957</issn><eissn>2328-8957</eissn><cop>US</cop><pub>Oxford University Press</pub><doi>10.1093/ofid/ofab466.729</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2328-8957
ispartof Open forum infectious diseases, 2021-12, Vol.8 (Supplement_1), p.S365-S366
issn 2328-8957
2328-8957
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8643844
source DOAJ Directory of Open Access Journals; Oxford Journals Open Access Collection; EZB-FREE-00999 freely available EZB journals; PubMed Central
subjects Poster Abstracts
title 530. Bamlanivimab (BAM) for SARS-CoV-2 Infection: Rates and Risk Factors for Hospitalization after Monoclonal Antibody Administration in a High-Risk Population
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-08T17%3A49%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmedcentral_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=530.%20Bamlanivimab%20(BAM)%20for%20SARS-CoV-2%20Infection:%20Rates%20and%20Risk%20Factors%20for%20Hospitalization%20after%20Monoclonal%20Antibody%20Administration%20in%20a%20High-Risk%20Population&rft.jtitle=Open%20forum%20infectious%20diseases&rft.au=Curtin,%20John%20M&rft.date=2021-12-04&rft.volume=8&rft.issue=Supplement_1&rft.spage=S365&rft.epage=S366&rft.pages=S365-S366&rft.issn=2328-8957&rft.eissn=2328-8957&rft_id=info:doi/10.1093/ofid/ofab466.729&rft_dat=%3Cpubmedcentral_cross%3Epubmedcentral_primary_oai_pubmedcentral_nih_gov_8643844%3C/pubmedcentral_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true